Ask Vendit Off-Topic Questions Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Ask Vendit Off-Topic Questions

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: MJ who wrote (3904)	1/15/2005 2:39:03 PM
From: Vendit™	Read Replies (1) of 8752

MJ, You were right. I just pulled this off of a search engine dealing with Nano medicine : Starpharma Awarded Its Third US Nanotechnology Patent Melbourne, Australia. November 20th, 2002 Starpharma Pooled Development Limited (ASX:SPL) has received notification of issue of US Patent Number 6464971 from the United States Patent and Trademark Office. The patent, entitled "Anionic or cationic dendrimer antimicrobial or antiparasitic compositions", has been issued to Starpharma Limited, a wholly-owned subsidiary of Starpharma Pooled Development Limited. This is the third of Starpharma's patents to receive final approval through the US system, and further consolidates the Company's worldwide dendrimer nanotechnology intellectual property. It also further consolidates Starpharma's substantial development pipeline in the area of dendrimer based pharmaceuticals. In addition to its own extensive intellectual property portfolio, Starpharma has exclusive commercialisation rights to all pharmaceutical applications arising out of the dendrimer patents of the US based company Dendritic Nanotechnologies Ltd (DNT). Starpharma's most recent quarterly update (31 Oct 2002) shows that its research into pharmaceutical applications of dendrimers is continuing to yield promising results in a broad range of major disease areas, including: West Nile Virus prion diseases (including Bovine Spongiform Encephalopathy or 'mad cow disease') colon cancer respiratory viruses sexually transmitted disease protection The Company is engaged in discussions with potential license partners to develop and commercialise both Starpharma and DNT intellectual property. John Raff said: "We are offering the opportunity for major pharmaceutical companies to develop new and improved drugs by incorporating our proprietary dendrimer based nanotechnology into their products." I'm not sure if you can access this link without being logged on as a user: nanotech-now.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next